164 related articles for article (PubMed ID: 27039055)
1. Loss of ATP13A2 impairs glycolytic function in Kufor-Rakeb syndrome patient-derived cell models.
Park JS; Koentjoro B; Davis RL; Sue CM
Parkinsonism Relat Disord; 2016 Jun; 27():67-73. PubMed ID: 27039055
[TBL] [Abstract][Full Text] [Related]
2. Parkinson's disease-associated human ATP13A2 (PARK9) deficiency causes zinc dyshomeostasis and mitochondrial dysfunction.
Park JS; Koentjoro B; Veivers D; Mackay-Sim A; Sue CM
Hum Mol Genet; 2014 Jun; 23(11):2802-15. PubMed ID: 24399444
[TBL] [Abstract][Full Text] [Related]
3. Hereditary Parkinsonism-Associated Genetic Variations in PARK9 Locus Lead to Functional Impairment of ATPase Type 13A2.
Park JS; Sue CM
Curr Protein Pept Sci; 2017; 18(7):725-732. PubMed ID: 26965689
[TBL] [Abstract][Full Text] [Related]
4. α-Synuclein-induced dopaminergic neurodegeneration in a rat model of Parkinson's disease occurs independent of ATP13A2 (PARK9).
Daniel G; Musso A; Tsika E; Fiser A; Glauser L; Pletnikova O; Schneider BL; Moore DJ
Neurobiol Dis; 2015 Jan; 73():229-43. PubMed ID: 25461191
[TBL] [Abstract][Full Text] [Related]
5. Zn²⁺ dyshomeostasis caused by loss of ATP13A2/PARK9 leads to lysosomal dysfunction and alpha-synuclein accumulation.
Tsunemi T; Krainc D
Hum Mol Genet; 2014 Jun; 23(11):2791-801. PubMed ID: 24334770
[TBL] [Abstract][Full Text] [Related]
6. Pathogenic effects of novel mutations in the P-type ATPase ATP13A2 (PARK9) causing Kufor-Rakeb syndrome, a form of early-onset parkinsonism.
Park JS; Mehta P; Cooper AA; Veivers D; Heimbach A; Stiller B; Kubisch C; Fung VS; Krainc D; Mackay-Sim A; Sue CM
Hum Mutat; 2011 Aug; 32(8):956-64. PubMed ID: 21542062
[TBL] [Abstract][Full Text] [Related]
7. ATP13A2 mutations impair mitochondrial function in fibroblasts from patients with Kufor-Rakeb syndrome.
Grünewald A; Arns B; Seibler P; Rakovic A; Münchau A; Ramirez A; Sue CM; Klein C
Neurobiol Aging; 2012 Aug; 33(8):1843.e1-7. PubMed ID: 22296644
[TBL] [Abstract][Full Text] [Related]
8. Lysosomal dysfunction in Parkinson disease: ATP13A2 gets into the groove.
Dehay B; Martinez-Vicente M; Ramirez A; Perier C; Klein C; Vila M; Bezard E
Autophagy; 2012 Sep; 8(9):1389-91. PubMed ID: 22885599
[TBL] [Abstract][Full Text] [Related]
9. Deficiency of ATP13A2 leads to lysosomal dysfunction, α-synuclein accumulation, and neurotoxicity.
Usenovic M; Tresse E; Mazzulli JR; Taylor JP; Krainc D
J Neurosci; 2012 Mar; 32(12):4240-6. PubMed ID: 22442086
[TBL] [Abstract][Full Text] [Related]
10. Regulation of intracellular manganese homeostasis by Kufor-Rakeb syndrome-associated ATP13A2 protein.
Tan J; Zhang T; Jiang L; Chi J; Hu D; Pan Q; Wang D; Zhang Z
J Biol Chem; 2011 Aug; 286(34):29654-62. PubMed ID: 21724849
[TBL] [Abstract][Full Text] [Related]
11. The role of ATP13A2 in Parkinson's disease: Clinical phenotypes and molecular mechanisms.
Park JS; Blair NF; Sue CM
Mov Disord; 2015 May; 30(6):770-9. PubMed ID: 25900096
[TBL] [Abstract][Full Text] [Related]
12. Altered apoptosis regulation in Kufor-Rakeb syndrome patients with mutations in the ATP13A2 gene.
Radi E; Formichi P; Di Maio G; Battisti C; Federico A
J Cell Mol Med; 2012 Aug; 16(8):1916-23. PubMed ID: 22117566
[TBL] [Abstract][Full Text] [Related]
13. Clinical and ultrastructural findings in an ataxic variant of Kufor-Rakeb syndrome.
Pietrzak A; Badura-Stronka M; Kangas-Kontio T; Felczak P; Kozubski W; Latos-Bielenska A; Wierzba-Bobrowicz T; Florczak-Wyspianska J
Folia Neuropathol; 2019; 57(3):285-294. PubMed ID: 31588715
[TBL] [Abstract][Full Text] [Related]
14. Kufor-Rakeb Syndrome/PARK9: One Novel and One Possible Recurring Ashkenazi ATP13A2 Mutation.
Inzelberg R; Estrada-Cuzcano A; Laitman Y; De Vriendt E; Friedman E; Jordanova A
J Parkinsons Dis; 2018; 8(3):399-403. PubMed ID: 29966207
[TBL] [Abstract][Full Text] [Related]
15. Dysregulated iron metabolism in C. elegans catp-6/ATP13A2 mutant impairs mitochondrial function.
Anand N; Holcom A; Broussalian M; Schmidt M; Chinta SJ; Lithgow GJ; Andersen JK; Chamoli M
Neurobiol Dis; 2020 Jun; 139():104786. PubMed ID: 32032734
[TBL] [Abstract][Full Text] [Related]
16. ATP13A2/PARK9 regulates endo-/lysosomal cargo sorting and proteostasis through a novel PI(3, 5)P2-mediated scaffolding function.
Demirsoy S; Martin S; Motamedi S; van Veen S; Holemans T; Van den Haute C; Jordanova A; Baekelandt V; Vangheluwe P; Agostinis P
Hum Mol Genet; 2017 May; 26(9):1656-1669. PubMed ID: 28334751
[TBL] [Abstract][Full Text] [Related]
17. ATP13A2/PARK9 regulates secretion of exosomes and α-synuclein.
Tsunemi T; Hamada K; Krainc D
J Neurosci; 2014 Nov; 34(46):15281-7. PubMed ID: 25392495
[TBL] [Abstract][Full Text] [Related]
18. Lysosomal Storage of Subunit c of Mitochondrial ATP Synthase in Brain-Specific Atp13a2-Deficient Mice.
Sato S; Koike M; Funayama M; Ezaki J; Fukuda T; Ueno T; Uchiyama Y; Hattori N
Am J Pathol; 2016 Dec; 186(12):3074-3082. PubMed ID: 27770614
[TBL] [Abstract][Full Text] [Related]
19. Common pathogenic effects of missense mutations in the P-type ATPase ATP13A2 (PARK9) associated with early-onset parkinsonism.
Podhajska A; Musso A; Trancikova A; Stafa K; Moser R; Sonnay S; Glauser L; Moore DJ
PLoS One; 2012; 7(6):e39942. PubMed ID: 22768177
[TBL] [Abstract][Full Text] [Related]
20. PARK9-associated ATP13A2 localizes to intracellular acidic vesicles and regulates cation homeostasis and neuronal integrity.
Ramonet D; Podhajska A; Stafa K; Sonnay S; Trancikova A; Tsika E; Pletnikova O; Troncoso JC; Glauser L; Moore DJ
Hum Mol Genet; 2012 Apr; 21(8):1725-43. PubMed ID: 22186024
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
